In the context of clinical trials for new cancer treatments, Type II errors can lead to the incorrect conclusion that a new treatment is not effective when it actually is. This can prevent potentially beneficial treatments from being approved and made available to patients. To mitigate this risk, clinical trials often use large sample sizes and rigorous statistical methods to reduce the likelihood of Type II errors.
